On August 22, 2024, Traphaco Joint Stock Company continued to affirm its leading position when it was honored for the 9th time by Forbes Vietnam Magazine in the list of 50 best listed companies in Vietnam in 2024. This achievement is not only a recognition of Traphaco's continuous efforts but also a clear demonstration of the success of the parallel development strategy of Eastern medicine - Western medicine. 
Ms. Dao Thuy Ha - Deputy General Director of Traphaco Joint Stock Company, on behalf of the Company, received the Cup of honoring the Top 50 Best Listed Companies in Vietnam in 2024 voted by Forbes. The list of 50 best listed companies in 2024 was announced by Forbes Vietnam based on the audited financial results report in 2023. Accordingly, the enterprises appearing in this list are "locomotives" of the economy and are typical representatives of the industries in which they operate. The 2024 list reflects the challenges of the economy when the internal difficulties of the Vietnamese economy in the past two years such as slowing exports, stagnant production, weak consumer market, and sluggish real estate market have made the representatives of this industry group less while the defensive industry group (utilities, food-beverage, pharmaceuticals, healthcare, etc.) is on the throne. In general, 2023-2024 is the period when Traphaco achieves a number of significant achievements for the company's development, continuing to adhere to the parallel strategy of Eastern medicine - Western medicine. The corporate governance capacity according to international practices of Traphaco's leadership team plays an important role in difficult economic times, ensuring that plans are implemented smoothly according to the set strategy, optimizing resources, minimizing waste and risks. According to the company's 2023 report, ETC revenue increased significantly, more than 23% compared to the previous year. Although ETC revenue does not account for a large proportion of Traphaco's scale, this is one of the most important factors ensuring Traphaco's strong development in the future. At the same time, the Non-Drug product group increased by 6% compared to the previous year, a good signal was recorded from revenue at pharmacy chains, the exploited product group also exceeded the target and grew by more than double digits compared to 2023, including the successful implementation of early stage technology transfer products. 
Traphaco delegation at the ceremony to honor the Top 50 best listed companies in Vietnam in 2024 In 2024, there are three core tasks that Traphaco needs to complete. The first is to implement the "EU-GMP Upgrade Project". Second, Traphaco will focus on enhancing its Research and Development capacity, including technology transfer. The third step that Traphaco will focus on is exporting products to the Southeast Asian market through Daewoong's global network. In the oriental medicine segment, the Company has researched and launched high-end product lines. Sales of the high-end oriental medicine group in 2023 increased by 1.6 times over the same period and increased by 5 times compared to 2020 when Boganic Premium was first launched, proving that high-quality product lines continue to have a solid position in the market. More exciting is the pharmaceutical segment, Traphaco focuses on new technology products, bioequivalent drugs and first generic drugs. These products are identified as high-quality pharmaceutical products, treating diseases with large market capacity and demand such as: cardiovascular, stomach, liver, bile, diabetes and infections. Up to now, Traphaco has had 10 products announced by the Ministry of Health as bioequivalent to original drugs, the production of technology transfer products with Daewoong Group has entered phase 3 with 7 products launched on the market such as Ursodeoxycholic Acid gallstone treatment drug, DW-TRA RebaTot stomach medicine, DW-TRA TimaRo blood lipid lowering drug. Coming soon is the product Bexita - a drug combining 2 active ingredients to treat diabetes, a new treatment trend that helps the product to be well tolerated, more effective, safer and has fewer side effects than monotherapy drugs. In 2024, the economy will continue to be difficult, complicated, the big challenge for the healthcare industry is the decline in income, affecting people's consumption demand. However, Traphaco still sets a growth target, with consolidated revenue of VND 2,485 billion, consolidated profit after tax of VND 303 billion, growth of 7% and 6% respectively compared to the previous year. After the first 6 months of the year, Traphaco basically completed the targets on sales, research on new products and comprehensive digital transformation projects. Traphaco's solid business foundations are demonstrated by financial indicators, combined with high assessments of non-financial factors such as sustainable development capacity, company position in the industry, source of profit, quality of corporate governance, business development prospects, industry prospects, etc. have brought the Company into the "List of 50 best listed companies" in 2024 voted by Forbes Vietnam. This is a testament to Traphaco's strong internal strength and breakthrough capacity after more than 5 decades of striving, to soon enter a new phase with many great goals ahead. 
Traphaco and representatives of businesses in the Top 50 best listed companies in Vietnam in 2024 took souvenir photos
Source: https://traphaco.com.vn/traphaco-tiep-tuc-toa-sang-khang-dinh-vi-the-hang-dau-trong-top-50-cong-ty-niem-yet-tot-nhat-viet-nam-2024 Ms. Dao Thuy Ha - Deputy General Director of Traphaco Joint Stock Company, on behalf of the Company, received the Cup of honoring the Top 50 Best Listed Companies in Vietnam in 2024 voted by Forbes. The list of 50 best listed companies in 2024 was announced by Forbes Vietnam based on the audited financial results report in 2023. Accordingly, the enterprises appearing in this list are "locomotives" of the economy and are typical representatives of the industries in which they operate. The 2024 list reflects the challenges of the economy when the internal difficulties of the Vietnamese economy in the past two years such as slowing exports, stagnant production, weak consumer market, and sluggish real estate market have made the representatives of this industry group less while the defensive industry group (utilities, food-beverage, pharmaceuticals, healthcare, etc.) is on the throne. In general, 2023-2024 is the period when Traphaco achieves a number of significant achievements for the company's development, continuing to adhere to the parallel strategy of Eastern medicine - Western medicine. The corporate governance capacity according to international practices of Traphaco's leadership team plays an important role in difficult economic times, ensuring that plans are implemented smoothly according to the set strategy, optimizing resources, minimizing waste and risks. According to the company's 2023 report, ETC revenue increased significantly, more than 23% compared to the previous year. Although ETC revenue does not account for a large proportion of Traphaco's scale, this is one of the most important factors ensuring Traphaco's strong development in the future. At the same time, the Non-Drug product group increased by 6% compared to the previous year, a good signal was recorded from revenue at pharmacy chains, the exploited product group also exceeded the target and grew by more than double digits compared to 2023, including the successful implementation of early stage technology transfer products. Traphaco delegation at the ceremony to honor the Top 50 best listed companies in Vietnam in 2024 In 2024, there are three core tasks that Traphaco needs to complete. The first is to implement the "EU-GMP Upgrade Project". Second, Traphaco will focus on enhancing its Research and Development capacity, including technology transfer. The third step that Traphaco will focus on is exporting products to the Southeast Asian market through Daewoong's global network. In the oriental medicine segment, the Company has researched and launched high-end product lines. Sales of the high-end oriental medicine group in 2023 increased by 1.6 times over the same period and increased by 5 times compared to 2020 when Boganic Premium was first launched, proving that high-quality product lines continue to have a solid position in the market. More exciting is the pharmaceutical segment, Traphaco focuses on new technology products, bioequivalent drugs and first generic drugs. These products are identified as high-quality pharmaceutical products, treating diseases with large market capacity and demand such as: cardiovascular, stomach, liver, bile, diabetes and infections. Up to now, Traphaco has had 10 products announced by the Ministry of Health as bioequivalent to original drugs, the production of technology transfer products with Daewoong Group has entered phase 3 with 7 products launched on the market such as Ursodeoxycholic Acid gallstone treatment drug, DW-TRA RebaTot stomach medicine, DW-TRA TimaRo blood lipid lowering drug. Coming soon is the product Bexita - a drug combining 2 active ingredients to treat diabetes, a new treatment trend that helps the product to be well tolerated, more effective, safer and has fewer side effects than monotherapy drugs. In 2024, the economy will continue to be difficult, complicated, the big challenge for the healthcare industry is the decline in income, affecting people's consumption demand. However, Traphaco still sets a growth target, with consolidated revenue of VND 2,485 billion, consolidated profit after tax of VND 303 billion, growth of 7% and 6% respectively compared to the previous year. After the first 6 months of the year, Traphaco basically completed the targets on sales, research on new products and comprehensive digital transformation projects. Traphaco's solid business foundations are demonstrated by financial indicators, combined with high assessments of non-financial factors such as sustainable development capacity, company position in the industry, source of profit, quality of corporate governance, business development prospects, industry prospects, etc. have brought the Company into the "List of 50 best listed companies" in 2024 voted by Forbes Vietnam. This is a testament to Traphaco's strong internal strength and breakthrough capacity after more than 5 decades of striving, to soon enter a new phase with many great goals ahead. Traphaco and representatives of businesses in the Top 50 best listed companies in Vietnam in 2024 took souvenir photos
Comment (0)